UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis

Journal of gastroenterology, 2020-05, Vol.55 (5), p.533-542

2020

Link zum Volltext

Verfügbarkeit prüfen

The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test

PloS one, 2016-02, Vol.11 (2), p.e0149230-e0149230

2016

Link zum Volltext

Verfügbarkeit prüfen

Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III)

Wiener Klinische Wochenschrift, 2017-11, Vol.129 (Suppl 3), p.135-158

2017

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis

United European gastroenterology journal, 2021-12, Vol.9 (10), p.1119-1127

2021

Link zum Volltext

Verfügbarkeit prüfen

Improving care for victims of violence in resource-poor settings such as Lusaka, Zambia: results of a low-budget intervention

Injury prevention, 2016-04, Vol.22 (2), p.144-148

2016

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy in hepatocellular carcinoma

Memo - Magazine of European medical oncology, 2020-06, Vol.13 (2), p.218-222

Hametner-Schreil, Stephanie

2020

Link zum Volltext

Verfügbarkeit prüfen

980 Improving care for victims of violence in resource-poor settings such as Lusaka, Zambia

Injury prevention, 2016-09, Vol.22 (Suppl 2), p.A349-A349

2016

Link zum Volltext

Verfügbarkeit prüfen

574 Enhancing cooperation of medical and social services to improve aid to victims of violence in Zambia

Injury prevention, 2016-09, Vol.22 (Suppl 2), p.A206-A206

2016

Link zum Volltext

Verfügbarkeit prüfen

Diagnostik- und Therapieleitfaden 2023 für PBC in Österreich: Primär biliäre Cholangitis frühzeitig erkennen und risikostratifiziert behandeln

Journal für gastroenterologische und hepatologische Erkrankungen, 2023-04, Vol.21 (1), p.21-25

2023

Link zum Volltext

Verfügbarkeit prüfen

Tuberculous sepsis during antiviral HCV triple therapy

Journal of hepatology, 2013-09, Vol.59 (3), p.637-638

2013

Link zum Volltext

Verfügbarkeit prüfen

Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study

Clinical gastroenterology and hepatology, 2023-04, Vol.21 (4), p.978-987.e2

2023

Link zum Volltext

Verfügbarkeit prüfen

VON WILLEBRAND FACTOR ANTIGEN (vWF-Ag): A NON-INVASIVE PREDICTOR OF TREATMENT RESPONSE AND SERIOUS ADVERSE EVENTS IN HCV PATIENTS WITH INTERFERON TRIPLE THERAPY

Digestive and liver disease, 2016-10, Vol.48 (10), p.1194-1199

2016

Link zum Volltext

Verfügbarkeit prüfen

Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C

The American journal of gastroenterology, 2016-05, Vol.111 (5), p.744-745

2016

Link zum Volltext

Verfügbarkeit prüfen

Empfehlungen zur Abklärung der Hepatosplenomegalie bei Erwachsenen unter besonderer Berücksichtigung von lysosomalen Speichererkrankungen

Journal für gastroenterologische und hepatologische Erkrankungen, 2021-07, Vol.19 (2), p.44-53

2021

Link zum Volltext

Verfügbarkeit prüfen

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

The New England journal of medicine, 2024-02, Vol.390 (6), p.497-509

2024

Link zum Volltext

Verfügbarkeit prüfen

The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test: e0149230

PloS one, 2016-02, Vol.11 (2)

2016

Link zum Volltext

Verfügbarkeit prüfen

Tuberculous sepsis during antiviral HCV triple therapy

Journal of hepatology, 2013, Vol.59 (3), p.637-638

2013

Link zum Volltext

Verfügbarkeit prüfen

Wave intensity of aortic root pressure as diagnostic marker of left ventricular systolic dysfunction

PloS one, 2017-06, Vol.12 (6), p.e0179938-e0179938

2017

Link zum Volltext

Verfügbarkeit prüfen

Noninvasive methods to assess pulse wave velocity: comparison with the invasive gold standard and relationship with organ damage

Journal of hypertension, 2015-05, Vol.33 (5), p.1023-1031

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(38)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis

The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test

Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III)

Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis

Improving care for victims of violence in resource-poor settings such as Lusaka, Zambia: results of a low-budget intervention

Immunotherapy in hepatocellular carcinoma

980 Improving care for victims of violence in resource-poor settings such as Lusaka, Zambia

574 Enhancing cooperation of medical and social services to improve aid to victims of violence in Zambia

Diagnostik- und Therapieleitfaden 2023 für PBC in Österreich: Primär biliäre Cholangitis frühzeitig erkennen und risikostratifiziert behandeln

Tuberculous sepsis during antiviral HCV triple therapy

Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study

VON WILLEBRAND FACTOR ANTIGEN (vWF-Ag): A NON-INVASIVE PREDICTOR OF TREATMENT RESPONSE AND SERIOUS ADVERSE EVENTS IN HCV PATIENTS WITH INTERFERON TRIPLE THERAPY

Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C

Empfehlungen zur Abklärung der Hepatosplenomegalie bei Erwachsenen unter besonderer Berücksichtigung von lysosomalen Speichererkrankungen

OS-127-YI - The risks of first hepatic decompensation and HCC remain constant during long-term follow-up and can be stratified by a one-time assessment after HCV-cure

The risks of first hepatic decompensation and HCC remain constant during long-term follow-up and can be stratified by a one-time assessment after HCV-cure

Validation and refinement of the Baveno VII criteria for risk stratification in compensated advanced chronic liver disease after HCV-cure

SAT-521 - Validation and refinement of the Baveno VII criteria for risk stratification in compensated advanced chronic liver disease after HCV-cure

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)

The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test: e0149230

Management of patients with chronic hepatitis C failing repeated courses of interferon‐free direct acting antiviral combination therapy

Tuberculous sepsis during antiviral HCV triple therapy

Wave intensity of aortic root pressure as diagnostic marker of left ventricular systolic dysfunction

Noninvasive methods to assess pulse wave velocity: comparison with the invasive gold standard and relationship with organ damage

Suchergebnisse filtern